Skip to main content

Day: February 21, 2024

trinamiX, Visionox and STMicroelectronics present cost-efficient, secure Face Authentication system for behind-OLED integration in smartphones

T4605D — Feb 21 2024 — Behind-OLED face authentication at MWC24_IMAGEBehind-OLED face authentication at MWC24trinamiX, Visionox and STMicroelectronics present cost-efficient, secure Face Authentication system for behind-OLED integration in smartphonesProduct-ready Face Authentication invisibly integrated behind smartphone displays on show at Mobile World Congress 2024 (trinamiX, Hall 6, booth E68; ST, Hall 7, Booth 7A61) System contains an integration-ready semi-transparent OLED display from Visionox, a high-performance global-shutter CMOS sensor from ST, trinamiX’ sensing module design and algorithms for secure liveness detectionIntegration into new smartphone series feasible within six to nine months at competitive system costLudwigshafen, Germany; Beijing, China; Geneva, Switzerland — February 21,...

Continue reading

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 21 February 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report full year 2023 results, before the US markets open on Wednesday, February 28, 2024. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. ET (1:00 p.m. GMT) to discuss their financial results and provide a business and portfolio update. Audio WebcastThe call will be webcast live and...

Continue reading

Brunswick Launches Maiden Drilling Campaign at Elrond

Figure 1Aerial view of the Arwen showingMONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce that it has begun construction of a winter road for a drilling campaign at the Elrond project, located in Eeyou Istchee-James Bay Region of Quebec. This maiden drilling campaign will begin in March and will test the Arwen spodumene-bearing pegmatite that was discovered during prospecting last September by the BRW team. The Arwen showing and the Elrond property have never been drilled. The Arwen pegmatite is exposed over a surface area measuring approximately 250 meters by 100 meters, dipping shallowly to the north. The outcrop is well mineralized and three representative grab samples returned values between 1 and 3% Li2O. The pegmatite remains...

Continue reading

ATHA Energy Provides Further Updates to Transaction With 92 Energy

VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) — ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to provide another update on its previously announced proposed acquisition transaction with 92 Energy Limited (ASX: 92E) (OTCQX: NTELF) (“92E”) further to its press releases dated December 7, 2023, January 25, 2024, and February 7, 2024. ATHA is pleased to announce that the independent expert of 92E, BDO Corporate Finance (WA) Pty Limited, has concluded that the proposed acquisition of 92E by ATHA is fair and reasonable and in the best interest of the shareholders of 92E (“92E Shareholders”). Additionally, the Federal Court of Australia has made orders approving, amongst other matters:the convening by 92E of a meeting of 92E Shareholders (the “Scheme Meeting”) to consider and vote on the scheme...

Continue reading

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update. To access the conference call:U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins. Participants should ask to be connected to the Editas Medicine Earnings Conference Call.The conference call will also be webcast and can be accessed from the “Investors” section of the Editas Medicine website at https://www.editasmedicine.com. A replay will be available at the same site approximately one hour after the...

Continue reading

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024 HOUSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc. (NASDAQ: BPTH) (the “Company”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that it intends to effect a reverse stock split of its outstanding common stock, par value $0.001 per share, at a ratio of 1-for-20. The reverse stock split will be effective as of 5:30 p.m., Eastern Time on February 22, 2024, and the Company’s common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on February 23, 2024 under the Company’s existing symbol “BPTH.” The Company’s common stock has been assigned a new...

Continue reading

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences: 2024 BIO CEO & Investor Conference (Panel)Panel Title: Reviewing Vaccine Pipeline Breakthroughs and BarriersDate and Time: Monday, February 26, 2024 at 2:00pm ETLocation: New York, NY IO360 Summit (Panel)Panel Title: How to use AI to Leverage Data from Patients in the Clinic to Iterate Next Gen ImmunotherapiesDate and Time: Tuesday, February 27, 2024 at 2:30pm ETLocation: New York, NY 44th Annual TD Cowen Healthcare Conference (Panel)Panel Title: Novel I-O Corporate PanelDate and Time: Monday, March 4, 2024 at 10:30am ETLocation: Boston, MA World...

Continue reading

Platinex Intersects Widespread Gold Mineralization in Maiden Drill Program at Heenan including 77.44 m of 0.40 g/t Au and 27.15 m of 0.55 g/t and Announces Board Reorganization

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PX) (“Platinex” or the “Company”) is pleased to announce results from the first phase of diamond drilling on the Heenan Property, part of the Heenan Mallard Gold Project located in the Swayze Greenstone Belt of the Abitibi northeastern Ontario and held through the South Timmins Mining Joint Venture (“South Timmins JV”) with Fancamp Exploration Ltd. Highlights:The program totalled 611.50 m with three drill holes completed over 50 m spacing and one undercut hole. All cross sections for the four holes are on the website.Several consistent wide zones of gold mineralization intersected from surface to 177m including:77.44 m of 0.40 g/t Au in hole HE23-02 and, 27.15 m of 0.55 g/t Au in hole HE-23-03 with higher-grade intercepts within...

Continue reading

Two of Oregon’s Favorite Craft Breweries Team Up With the Portland Timbers as Official Craft Beer Sponsors

10 Barrel Brewing and Widmer Brothers Sign a Multi-Year Deal That Includes Creation Of First Standing Room Only Section In The StadiumWidmer Brothers and 10 Barrel will become the official craft beer partners of the Portland TimbersPictured: The Iconic Portland StadiumPORTLAND, Ore., Feb. 21, 2024 (GLOBE NEWSWIRE) — 10 Barrel Brewing Co. (“10 Barrel Brewing Co.” or “10 Barrel”), a trailblazer in the craft brewing industry, and Widmer Brothers Brewing (“Widmer Brothers”), the original Portland craft brewer, both subsidiaries of Tilray Brands, Inc. (“Tilray”) (NASDAQ: TLRY and TSX: TLRY), are pleased to announce a multi-year, exclusive partnership with the Portland Timbers (“Timbers”). Widmer Brothers and 10 Barrel will become the official craft beer partners of the Timbers. At the same time, Pub Beer has been named as...

Continue reading

Giyani closes US$10 million investment from ARCH

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) — Giyani Metals Corp. (TSXV:EMM, GR:A2DUU8) (“Giyani” or the “Company”), developer of the K.Hill battery-grade manganese project in Botswana (“K.Hill” or the “Project”) is pleased to announce that on February 20, 2024 it closed the US$10 million investment by ARCH Sustainable Resources Fund LP (“ARCH”) announced on January 24, 2024 (“Closing”). The Company and ARCH have satisfied all necessary conditions precedent to Closing and US$10 million has now been received by the Company. The ARCH funding fulfils a key condition for drawdown of the US$16 million convertible loan facilities (the “IDC Facility”) secured by Giyani from the Industrial Development Corporation (“IDC”) of South Africa Limited and forms part of a larger aggregate US$26 million funding package to progress K.Hill to Final Investment...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.